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2004–October 2005) were obtained, and a dose interchange
table identifying the statin switches providing an LDL-C lower-
ing effect within 10% of the entry drug was developed. The study
assumed all patients requiring a higher level of LDL reduction
would switch from other equivalent statin doses to simvastatin
20 mg daily. Two different assumptions with four cost scenarios
for future generic simvastatin prices were tested: 20% rebate for
branded statins, a 50% discount rate, and $5 generic and $15
brand co-payments (assumption 1) and 20% rebate for branded
statins, a 60% discount rate, and $10 generic and $30 brand co-
payments (assumption 2). RESULTS: With the baseline assump-
tions in the study, total costs to TPPs for branded statins were
$5.57B (assumption 1) and $4.62B (assumption 2). Switching
patients to generic simvastatin lowered total costs to $4.54B and
$3.25B, respectively, providing potential costs savings for TPPs
of $1.03B to $1.37B. One-way sensitivity analyses varying the
purchasing discount rate for generic simvastatin from 40%–75%
in assumption 1, found the range of cost savings to be $0.06B–
$3.46B; varying the discount rate from 50%–75% in 
assumption 2 found a range of cost savings of $0.4B–$2.83B.
CONCLUSION: The switch to generic simvastatin 20 mg for
patients requiring cholesterol reduction yielded potential annual
cost savings for TPPs over one year. Other long-term studies
focusing on the economic impacts on TPPs are encouraged to
evaluate potential cost savings following the availability of other
generic statin drugs.
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OBJECTIVES: Recently published data have increased interest
in high clopidogrel loading doses (>300 mg) in acute coronary
syndrome (ACS) patients undergoing percutaneous coronary
intervention (PCI). The purpose of this study was to examine
clopidogrel patterns of use in the hospital setting in ACS/PCI
patients residing in Europe. METHODS: This was a retrospec-
tive study using the IMS Health Acute Cardiovascular Analyzer.
This is a physician-reported registry in Germany, France, Italy,
Spain, and the UK. Data collection timeframe was January–
November 2005. The standard dose clopidogrel group was
deﬁned as <300 mg. Demographic and health characteristics
were compiled for the entire cohort and by country. RESULTS:
Over 400 cardiologists reported data on 4393 ACS patients who
received clopidogrel and underwent PCI. Patient count by
country was: Germany-1117, France-1048, Italy-598, Spain-
993, UK-637. Mean age was 63 + 12.2 (SD) years; 71% were
male. Common comorbidities and risk factors were: hyperten-
sion 66%, dyslipidemia 63%, diabetes 31%, prior myocardial
infarction (MI) 13%. Medications prior to admission were:
clopidogrel 17%, statins 26%, aspirin 27%. The index diagno-
sis was: ST-elevation MI 45%, non ST-elevation MI 29% and
unstable angina 26%. Timing of clopidogrel administration in
relation to PCI was: 23.9% pre-PCI (of which, 2% were >12
hours pre-PCI), 10.9% at PCI and 53.4% after PCI. Loading
dose ranged from 75–900 mg. Dosage <300 mg by country was:
Germany 80%, France 85%, Italy 91%, Spain 95%, UK 81%.
Approximately 96% of patients were discharged on clopidogrel
and the most common planned duration was 6–12 months
(56.6%) followed by >12 months (13.6%). CONCLUSIONS:
These recent data indicate many patients did not receive clopi-
dogrel prior to PCI and higher loading doses (>300 mg) were
uncommon. The vast majority of patients received clopidogrel
upon discharge with planned duration of therapy of 6–12
months. These data may be useful benchmarks for later com-
parison to treatment guidelines.
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OBJECTIVES: To compare claims data on bleeding complica-
tions in ACS patients treated with clopidogrel vs. aspirin/heparin
undergoing catheterization prior to coronary artery bypass graft-
ing (CABG). METHODS: Patients >18 years of age with an ACS
diagnosis between 2000 and 2004 were identiﬁed using ICD-9
codes. Treatment patterns and outcomes were compared across
two cohorts: patients on clopidogrel +/− aspirin, heparin, or
IIbIIIa antagonists, and those on aspirin or heparin only. Claims
for CABG and catheterization prior to CABG were evaluated.
Among CABG patients who received clopidogrel, distribution of
days clopidogrel was discontinued pre-surgery was examined.
Claims related to bleeding complications among patients with
catheterization prior to CABG were evaluated using logistic
regression controlling for age, race, time to CABG, IIbIIIa 
exposure, and hospital size. RESULTS: We identiﬁed 25,289
clopidogrel patients and 21,688 aspirin/heparin patients. The
clopidogrel cohort was signiﬁcantly younger (65.6 versus 69.7,
p < 0.0001) with a higher proportion of male patients (62.8%
versus 54.7%, p < 0.0001). A total of 2535 clopidogrel patients
(10%) and 4358 aspirin/heparin patients (20.1%)underwent
CABG; of those, 1633 clopidogrel (64.4%) and 2053 aspirin/
heparin (47.1%) patients underwent catheterization prior to
surgery during the index admission. Among these clopidogrel
patients, 1791 (70.6%) discontinued clopidogrel prior to CABG;
a majority discontinued either the day of (41%) or the day before
(20.5%) surgery. Among patients undergoing catheterization
prior to CABG, claims related to bleeding complications were
signiﬁcantly more likely in the clopidogrel cohort compared to
the aspirin/heparin cohort after adjusting for covariates (OR
1.84, 95%CI 1.08–3.13). CONCLUSION: A majority of ACS
patients treated with clopidogrel and undergoing catheterization
and CABG discontinue clopidogrel closer to CABG than the rec-
ommended ﬁve days pre-surgery (US Package Insert). Addition-
ally, such patients may be at higher risk for bleeding than patients
treated with aspirin/heparin only.
PCV70
MANAGEMENT AND OUTCOMES IN THE CARE OF ATRIAL
FIBRILLATION IN GERMANY (MOCA)
Bruggenjurgen B1, McBride D2,Willich SN1
1Charite University Medical Center, Berlin, Germany, 2Institute for
Social Medicine, Epidemiology and Health Economics, Berlin,
Germany
OBJECTIVES: Atrial ﬁbrillation (AF) is the most common heart
arrhythmia affecting more than 6% of elderly people. The
annual risk of stroke in patients with AF not taking Vitamin-K
antagonists (VKAs) is 3–5%. Anticoagulation with a prothrom-
bin time (INR) of 2–3 has demonstrated effective primary pro-
phylaxis. This multi-centre observational study was conducted
to gain knowledge of the current treatment patterns of AF in
Germany, their clinical results and related resource utilization.
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METHODS: A total of 361 patients with AF (mean age 71 ± 9,
61% male) in 45 physician practices throughout Germany were
recruited. 3-month retrospective and 6-month prospective clini-
cal data including INR values and anticoagulation strategy were
obtained from the physician chart through standardised ques-
tionnaire. Patient health-related and disease-speciﬁc quality of
life was assessed with the SF-36 and MacNew heart disease
instruments. The patient completed a standardised questionnaire
at three and six months, which documented hospitalisations,
medications, and complications, as well as quality of life, patient
satisfaction and compliance. Three hundred-four (84%) patients
completed the entire study. RESULTS: Of all patients, 90% had
been treated with VKAs at some time since AF-diagnosis, 88%
were still on treatment. 10% of the patients received aspirin as
their anticoagulation therapy. INR was measured at least once a
month in over 70% of the patients. INR values were 56% of the
time within, 14% below and 30% over the target range. SF-36
results were similar to patients of comparable age and health.
Fifty-ﬁve percent of patients reported they were always or mostly
satisﬁed with their treatment and 66% stated they complied with
their prescribed treatment most or all of the time. CONCLU-
SIONS: This study presents German “real-life” data in treating
patients with AF and identiﬁes the potential to advance the
quality of care particularly with respect to anticoagulation.
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PHARMACOECONOMIC ANALYSIS OF TREATMENT OF
HYPERTENSION IN CLINICAL CENTER OF SERBIA-
PHARMACY AND MEDICAL SUPPLY
Simic G
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OBJECTIVE: Rational administration of drugs takes into
account drug price/type,pharmaceutical form, unit dose price,
associating success of a treatment with a given drug or drugs
with expenses related to the speciﬁc therapy. The paper is aimed
at: analysis of antihypertensive therapy prescription practice
along with economic parameters and analysis of consumption of
antihypertensive drugs in the Clinical Center of Serbia (CCS) in
accordance with the National Guide to Prevention of Ischemic
Disease. In spite of the high distribution of other heart diseases
in the structure of cardiovascular deaths, Serbia is, based on the
WHO data, classiﬁed into the group of countries with relatively
high risk of deaths associated with coronary diseases, among
both males and females aged between 40 and 49 years.
METHODS: The study was carried out at the CCS based on the
data provided by the Pharmacy and Medical Supply. All the
drugs mentioned in the analyses are registered in Serbia and 
the costs of the consumed drugs are reimbursed (100%) by the
Republic Health Insurance Fund. The analysis includes con-
sumption of drugs (according to groups) intended for treatment
of hypertension in CCS over the six-month period. Consump-
tion-based method is used as a quantiﬁcation method. RESULTS:
The patients were administered either single or combined drug
antihypertensive therapy. All groups of the studied drugs were
proved to lower arterial blood pressure, reduce morbidity and
mortality associated with the cardiovascular and cerebrovascu-
lar diseases, which was the basic aim of the applied therapy.
Diuretics and beta-blockers are most common drugs in treatment
of hypertension and their efﬁcacy and safety are best docu-
mented. CONCLUSION: Serbia needs restructuring of the
health care system and introduction of non-budgetary ﬁnancing,
adequate validation of health care services, privatization of
public sector and new legal regulations corresponding to the
changed economic environment.
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OBJECTIVE: The aim of this study was to review randomized
controlled trials (RCTs) comparing Valsartan 20/40/80 mg,
Telmisartan 80/160 mg, Losartan 50/100 mg and Irbesartan
75/150 mg at starting doses. A literature review of ARBs has not
been previously performed. METHODS: Published literature
was reviewed using OVID Medline, Embase, PubMed and
Cochrane databases, cut-off date June 8th, 2006, as sources of
data and the abstracted data were recorded into structured
forms. The quality of selected studies was assessed by CRD
Report No 4, University of York. Search terms included “mild
hypertension”, “moderate hypertension”, “anti-hypertensive
agents” and others combined with the speciﬁc drug terms.
Studies included were either “head-to-head” trials or random-
ized, double-blind or open label placebo-controlled trials
(RCTs). Clinical measurement of blood pressure included not
only ambulatory blood pressure monitoring (ABPM), but cuff
BP and sphygmomanometer also. Patient population was deﬁned
as mild-to-moderate hypertension with no concomitant diseases.
RESULTS: Forty-seven studies were included in the analysis.
Duration of treatment was typically 8 to 12 weeks. Sample size
ranged between 25 and 14820 patients. Mean age of sample
ranged between 47 and 63 years. Of the selected literature, 29
studies were head-to-head trials, 20 were RCTs versus placebo
and 8 were dose-response trials of the regimen. With respect to
BP measurements, 14 studies used ABPM in contrast to 25 that
used clinic BP. The remaining 8 reported both. With respect to
study design 3 studies were meta-analyses, 25 were double-blind
RCTs, 1 was a single-blind single-arm trial and 11 were open-
label studies. 11 studies included either forced or elective titra-
tion. Finally, from the sample, irbesartan had the less retrieval,
given that it is the newer agent of all. CONCLUSION: All studies
complied with the CRD Report No 4 quality assessment crite-
ria, University of York. The literature review was performed to
be used for meta-analytic purposes.
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ANALYSIS OF COST AND EFFECTIVENESS DATA USING
RANDOM PERMUTATION METHODS
Kolm P
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OBJECTIVES: Analysis of cost-effectiveness in clinical trials
often employs the incremental cost-effectiveness ratio (ICER) as
an index of cost-effectiveness. Because the index is a ratio of cost
differences divided by effect differences, and non-normally dis-
tributed, bootstrap methods are often used to assess its distrib-
ution. Conﬁdence intervals are potentially ambiguous because
ICERs with the same sign can have different interpretations
depending on their location in the cost-effectiveness plane. The
objective of this study was to use random permutation methods
in conjunction with the bootstrap to assess whether the cost and
effectiveness distribution differs from what would be expected
by chance. METHODS: Assuming treatment effectiveness, cost
data are simulated that follow normal, gamma and triangular
distributions. Bootstrap methods are employed to estimate the
cost and effectiveness distribution. The data are then randomly
permuted and the distribution compared with the bootstrap 
distribution. RESULTS: Random permutations for all simulated
cost distributions indicated an expected proportion of 0.25 
of cost and effectiveness pairs in each quadrant of the cost-
